IGFBP-3 Antibody (MM0342-6U23) - Azide and BSA Free

Novus Biologicals | Catalog # NBP2-12364

Novus Biologicals
Loading...

Key Product Details

Species Reactivity

Validated:

Human

Cited:

Human

Applications

Validated:

Immunohistochemistry, Immunohistochemistry-Paraffin, Western Blot

Cited:

Immunohistochemistry-Paraffin

Label

Unconjugated

Antibody Source

Monoclonal Mouse IgG2 Clone # MM0342-6U23

Format

Azide and BSA Free
Loading...

Product Specifications

Immunogen

Human recombinant IGFBP-3

Clonality

Monoclonal

Host

Mouse

Isotype

IgG2

Scientific Data Images for IGFBP-3 Antibody (MM0342-6U23) - Azide and BSA Free

IGFBP-3 Antibody (MM0342-6U23) - Azide and BSA Free

Western Blot: IGFBP-3 Antibody (MM0342-6U23) - Azide and BSA Free [NBP2-12364] -

BoTA-induced endometrial regeneration mediated by IGFBP3-dependent OPN proteolytic cleavage in a thin endometrium mouse model A Venn diagram of DEGs from EtOH-treated vs. saline-treated uteri (GSE207379) and BoTA-treated vs. saline-treated (GSE146934) displaying a shared gene with a reciprocal expression; Igfbp3. B Gene–gene network analysis of DEGs of EtOH-treated vs. saline-treated uteri categorized in CC GO terms displaying a shared gene; Spp1C Immunoblotting analysis of IGFBP3 and OPN in BoTA-treated thin endometrium compared to saline-treated group. D Immunoblotting analysis of OPN in BoTA-treated thin endometrium compared to IGFBP3-treated thin endometrium. beta -actin was used as a loading control. E An experimental schedule for an application of IGFBP3 neutralizing antibody together with BoTA. F Immunoblotting analysis of IGFBP3 and OPN in response to IGFBP3 neutralizing antibody treatment. beta -actin was used as a loading control. G Immunostaining of IGFBP3 in saline-treated, BoTA-treated, and BoTA with IGFBP-3 neutralizing antibody-treated thin endometrium. Upper panel shows the expression of IGFBP3 in the whole region of uterus and the indicated region with a box is magnified in lower panel. Scale bar; 100 um. H Immunostaining of active-OPN in saline-treated, BoTA-treated, and BoTA with IGFBP3 neutralizing antibody-treated thin endometrium. Upper panel shows the expression of active-OPN in the whole region of uterus and the indicated regions (LE luminal epithelium, GE glandular epithelium) with boxes are magnified in lower panel. Scale bar: 100 um. I H&E images for saline-, BoTA-, and BoTA with IGFBP3 neutralizing antibody-treated uteri. Scale bar: 100 um Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/36602651), licensed under a CC-BY license. Not internally tested by Novus Biologicals.
IGFBP-3 Antibody (MM0342-6U23) - Azide and BSA Free

Western Blot: IGFBP-3 Antibody (MM0342-6U23) - Azide and BSA Free [NBP2-12364] -

BoTA-induced endometrial regeneration mediated by IGFBP3-dependent OPN proteolytic cleavage in a thin endometrium mouse model A Venn diagram of DEGs from EtOH-treated vs. saline-treated uteri (GSE207379) and BoTA-treated vs. saline-treated (GSE146934) displaying a shared gene with a reciprocal expression; Igfbp3. B Gene–gene network analysis of DEGs of EtOH-treated vs. saline-treated uteri categorized in CC GO terms displaying a shared gene; Spp1C Immunoblotting analysis of IGFBP3 and OPN in BoTA-treated thin endometrium compared to saline-treated group. D Immunoblotting analysis of OPN in BoTA-treated thin endometrium compared to IGFBP3-treated thin endometrium. beta -actin was used as a loading control. E An experimental schedule for an application of IGFBP3 neutralizing antibody together with BoTA. F Immunoblotting analysis of IGFBP3 and OPN in response to IGFBP3 neutralizing antibody treatment. beta -actin was used as a loading control. G Immunostaining of IGFBP3 in saline-treated, BoTA-treated, and BoTA with IGFBP-3 neutralizing antibody-treated thin endometrium. Upper panel shows the expression of IGFBP3 in the whole region of uterus and the indicated region with a box is magnified in lower panel. Scale bar; 100 um. H Immunostaining of active-OPN in saline-treated, BoTA-treated, and BoTA with IGFBP3 neutralizing antibody-treated thin endometrium. Upper panel shows the expression of active-OPN in the whole region of uterus and the indicated regions (LE luminal epithelium, GE glandular epithelium) with boxes are magnified in lower panel. Scale bar: 100 um. I H&E images for saline-, BoTA-, and BoTA with IGFBP3 neutralizing antibody-treated uteri. Scale bar: 100 um Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/36602651), licensed under a CC-BY license. Not internally tested by Novus Biologicals.
IGFBP-3 Antibody (MM0342-6U23) - Azide and BSA Free

Western Blot: IGFBP-3 Antibody (MM0342-6U23) - Azide and BSA Free [NBP2-12364] -

BoTA-induced endometrial regeneration mediated by IGFBP3-dependent OPN proteolytic cleavage in a thin endometrium mouse model A Venn diagram of DEGs from EtOH-treated vs. saline-treated uteri (GSE207379) and BoTA-treated vs. saline-treated (GSE146934) displaying a shared gene with a reciprocal expression; Igfbp3. B Gene–gene network analysis of DEGs of EtOH-treated vs. saline-treated uteri categorized in CC GO terms displaying a shared gene; Spp1C Immunoblotting analysis of IGFBP3 and OPN in BoTA-treated thin endometrium compared to saline-treated group. D Immunoblotting analysis of OPN in BoTA-treated thin endometrium compared to IGFBP3-treated thin endometrium. beta -actin was used as a loading control. E An experimental schedule for an application of IGFBP3 neutralizing antibody together with BoTA. F Immunoblotting analysis of IGFBP3 and OPN in response to IGFBP3 neutralizing antibody treatment. beta -actin was used as a loading control. G Immunostaining of IGFBP3 in saline-treated, BoTA-treated, and BoTA with IGFBP-3 neutralizing antibody-treated thin endometrium. Upper panel shows the expression of IGFBP3 in the whole region of uterus and the indicated region with a box is magnified in lower panel. Scale bar; 100 um. H Immunostaining of active-OPN in saline-treated, BoTA-treated, and BoTA with IGFBP3 neutralizing antibody-treated thin endometrium. Upper panel shows the expression of active-OPN in the whole region of uterus and the indicated regions (LE luminal epithelium, GE glandular epithelium) with boxes are magnified in lower panel. Scale bar: 100 um. I H&E images for saline-, BoTA-, and BoTA with IGFBP3 neutralizing antibody-treated uteri. Scale bar: 100 um Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/36602651), licensed under a CC-BY license. Not internally tested by Novus Biologicals.
IGFBP-3 Antibody (MM0342-6U23) - Azide and BSA Free

Western Blot: IGFBP-3 Antibody (MM0342-6U23) - Azide and BSA Free [NBP2-12364] -

BoTA-induced endometrial regeneration mediated by IGFBP3-dependent OPN proteolytic cleavage in a thin endometrium mouse model A Venn diagram of DEGs from EtOH-treated vs. saline-treated uteri (GSE207379) and BoTA-treated vs. saline-treated (GSE146934) displaying a shared gene with a reciprocal expression; Igfbp3. B Gene–gene network analysis of DEGs of EtOH-treated vs. saline-treated uteri categorized in CC GO terms displaying a shared gene; Spp1C Immunoblotting analysis of IGFBP3 and OPN in BoTA-treated thin endometrium compared to saline-treated group. D Immunoblotting analysis of OPN in BoTA-treated thin endometrium compared to IGFBP3-treated thin endometrium. beta -actin was used as a loading control. E An experimental schedule for an application of IGFBP3 neutralizing antibody together with BoTA. F Immunoblotting analysis of IGFBP3 and OPN in response to IGFBP3 neutralizing antibody treatment. beta -actin was used as a loading control. G Immunostaining of IGFBP3 in saline-treated, BoTA-treated, and BoTA with IGFBP-3 neutralizing antibody-treated thin endometrium. Upper panel shows the expression of IGFBP3 in the whole region of uterus and the indicated region with a box is magnified in lower panel. Scale bar; 100 um. H Immunostaining of active-OPN in saline-treated, BoTA-treated, and BoTA with IGFBP3 neutralizing antibody-treated thin endometrium. Upper panel shows the expression of active-OPN in the whole region of uterus and the indicated regions (LE luminal epithelium, GE glandular epithelium) with boxes are magnified in lower panel. Scale bar: 100 um. I H&E images for saline-, BoTA-, and BoTA with IGFBP3 neutralizing antibody-treated uteri. Scale bar: 100 um Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/36602651), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Applications for IGFBP-3 Antibody (MM0342-6U23) - Azide and BSA Free

Application
Recommended Usage

Immunohistochemistry

1:20-200

Immunohistochemistry-Paraffin

1:20-1:200

Western Blot

1:500-1:2000
Application Notes
This IGFBP3 antibody (clone MM0342-6U23) is useful for Western Blot and Immunohistochemistry-Paraffin applications. In its IHC-P validation, the antigen retrieval was performed by incubation of sections with Proteinase K (20ug/ml in PBS) for 15min at room temperature (Note: the length of PK exposure should be optimized by the user as it may depend upon the variation of fixatives and length of fixation applied to a particular specimen).

Formulation, Preparation, and Storage

Purification

Protein G purified

Reconstitution

Reconstitute with sterilized PBS to a final concentration of 0.5 mg/ml.

Formulation

Lyophilized from a 0.2 um filtered solution in PBS. 0.025 mg size is provided in liquid form, PBS

Format

Azide and BSA Free

Preservative

No Preservative

Concentration

LYOPH mg/ml

Shipping

The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Store at -20C. Avoid freeze-thaw cycles.

Calculators

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Background: IGFBP-3

IGFBP3 is a member of the insulin-like growth factor binding protein (IGFBP) family and encodes a protein with an IGFBP domain and a thyroglobulin type-I domain. The protein forms a ternary complex with insulin-like growth factor acid-labile subunit (IGFALS) and either insulin-like growth factor (IGF) I or II. In this form, it circulates in the plasma, prolonging the half-life of IGFs and altering their interaction with cell surface receptors. Alternate transcriptional splice variants, encoding different isoforms, have been characterized. [provided by RefSeq]

Long Name

Insulin-like Growth Factor Binding Protein 3

Alternate Names

IGFBP3

Gene Symbol

IGFBP3

UniProt

Additional IGFBP-3 Products

Product Documents for IGFBP-3 Antibody (MM0342-6U23) - Azide and BSA Free

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot or batch number in the search box below.

Product Specific Notices for IGFBP-3 Antibody (MM0342-6U23) - Azide and BSA Free

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Citations for IGFBP-3 Antibody (MM0342-6U23) - Azide and BSA Free

Customer Reviews for IGFBP-3 Antibody (MM0342-6U23) - Azide and BSA Free

There are currently no reviews for this product. Be the first to review IGFBP-3 Antibody (MM0342-6U23) - Azide and BSA Free and earn rewards!

Have you used IGFBP-3 Antibody (MM0342-6U23) - Azide and BSA Free?

Submit a review and receive an Amazon gift card!

$25/€18/£15/$25CAN/¥2500 Yen for a review with an image

$10/€7/£6/$10CAN/¥1110 Yen for a review without an image

Submit a review
Amazon Gift Card

Protocols

Find general support by application which include: protocols, troubleshooting, illustrated assays, videos and webinars.

FAQs

No product specific FAQs exist for this product.

View all FAQs for Antibodies